Tried, true and new—mastering treatments

Here are a few treatment options we’re especially proud of:

  • Helping patients manage PHACES syndrome, a rare condition marked by hemangiomas along with birth defects of the heart, brain, skin, eyes or arteries. We’ve also been involved with the international PHACES registry.
  • Managing lymphangiomatosis, a rare disease of the lymphatic system, using interferon treatment and other new treatments such as the drug Rapamycin.
  • Treating complicated vascular malformations with embolization and sclerotherapy procedures using new drugs such as Bleomycin.
  • Using new types of laser therapy to treat vascular anomalies.


At Children’s, we focus on research and innovations that make a difference at the bedside. From improving day-to-day quality of life for children and teens, to developing new pain management approaches and adopting cutting-edge technologies, our research is completely kid and family-focused.

Children’s is engaged in many types of research, including investigator-initiated studies (led by a Children’s clinician), as well as externally sponsored multicenter trials, observational studies and registries.

Research studies are ongoing in all areas of the hospital and clinics, but read more about vascular anomalies research below:

  • Since 2009, our team has treated 90 infants and children with hemangiomas, or benign tumors, with a drug called Propranolol. The results have revolutionized the treatment of hemangiomas in children. And we’re spreading the word. Our experts reported these findings at the annual meeting of the American Society of Pediatric Hematology/Oncology.
  • Stephen Nelson, MD, our team’s medical director and pediatric hematologist, participated in a study that found the drug Sirolimus was effective in treating children and young adults with complicated vascular anomalies. The study appeared in the March 28, 2011 issue of the journal Pediatric Blood Cancer. Stephen Nelson, MD, was also part of a consensus group that published guidelines for treatment of Kaposiform hemangioendothelioma. The guidelines were published in the July 2013 issue of the Journal of Pediatrics.
  • James Sidman, MD, surgical director of the vascular anomalies program, was part of a team whose study, “Assessment of Pulsed-Dye Laser Therapy for Pediatric Cutaneous Vascular Anomalies,” was published in the Sept. 5, 2013 National Center for Biotechnology Information.



At Children’s, we know how important reliable information about conditions and illnesses is.